Chemotherapy for Late-Stage Cancer Patients

Meta-Analysis of Complete Response Rates

Derek Abbott, Martin L. Ashdown, Andrew P. Robinson, Steven L. Yatomi-Clarke, M. Luisa Ashdown, Andrew Allison, Svetomir Nenad Markovic, Brendon J. Coventry

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are generally low, with few exceptions, regardless of the solid cancer type or drug regimen. We investigated CR rates reported in the literature for clinical trials using chemotherapy alone, across a wide range of tumour types and chemotherapeutic regimens, to determine an overall CR rate for late-stage cancers. A total of 141 reports were located using the PubMed database. A meta-analysis was performed of reported CR from 68 chemotherapy trials (total 2732 patients) using standard agents across late-stage solid cancers-a binomial model with random effects was adopted. Mean CR rates were compared for different cancer types, and for chemotherapeutic agents with different mechanisms of action, using a logistic regression. Our results showed that the CR rates for chemotherapy treatment of late-stage cancer were generally low at 7.4%, regardless of the cancer type or drug regimen used. We found no evidence that CR rates differed between different chemotherapy drug types, but amongst different cancer types small CR differences were evident, although none exceeded a mean CR rate of 11%. This remarkable concordance of CR rates regardless of cancer or therapy type remains currently unexplained, and motivates further investigation.

Original languageEnglish (US)
Article number232
Pages (from-to)1
Number of pages1
JournalF1000Research
Volume4
DOIs
StatePublished - 2015

Fingerprint

Chemotherapy
Meta-Analysis
Drug Therapy
Neoplasms
Pharmaceutical Preparations
Logistics
Tumors
Statistical Models
PubMed
Logistic Models
Clinical Trials
Databases

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Abbott, D., Ashdown, M. L., Robinson, A. P., Yatomi-Clarke, S. L., Ashdown, M. L., Allison, A., ... Coventry, B. J. (2015). Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates. F1000Research, 4, 1. [232]. https://doi.org/10.12688/f1000research.6760.1

Chemotherapy for Late-Stage Cancer Patients : Meta-Analysis of Complete Response Rates. / Abbott, Derek; Ashdown, Martin L.; Robinson, Andrew P.; Yatomi-Clarke, Steven L.; Ashdown, M. Luisa; Allison, Andrew; Markovic, Svetomir Nenad; Coventry, Brendon J.

In: F1000Research, Vol. 4, 232, 2015, p. 1.

Research output: Contribution to journalArticle

Abbott, D, Ashdown, ML, Robinson, AP, Yatomi-Clarke, SL, Ashdown, ML, Allison, A, Markovic, SN & Coventry, BJ 2015, 'Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates', F1000Research, vol. 4, 232, pp. 1. https://doi.org/10.12688/f1000research.6760.1
Abbott D, Ashdown ML, Robinson AP, Yatomi-Clarke SL, Ashdown ML, Allison A et al. Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates. F1000Research. 2015;4:1. 232. https://doi.org/10.12688/f1000research.6760.1
Abbott, Derek ; Ashdown, Martin L. ; Robinson, Andrew P. ; Yatomi-Clarke, Steven L. ; Ashdown, M. Luisa ; Allison, Andrew ; Markovic, Svetomir Nenad ; Coventry, Brendon J. / Chemotherapy for Late-Stage Cancer Patients : Meta-Analysis of Complete Response Rates. In: F1000Research. 2015 ; Vol. 4. pp. 1.
@article{75981614e8744be189baa07eab12028f,
title = "Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates",
abstract = "Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are generally low, with few exceptions, regardless of the solid cancer type or drug regimen. We investigated CR rates reported in the literature for clinical trials using chemotherapy alone, across a wide range of tumour types and chemotherapeutic regimens, to determine an overall CR rate for late-stage cancers. A total of 141 reports were located using the PubMed database. A meta-analysis was performed of reported CR from 68 chemotherapy trials (total 2732 patients) using standard agents across late-stage solid cancers-a binomial model with random effects was adopted. Mean CR rates were compared for different cancer types, and for chemotherapeutic agents with different mechanisms of action, using a logistic regression. Our results showed that the CR rates for chemotherapy treatment of late-stage cancer were generally low at 7.4{\%}, regardless of the cancer type or drug regimen used. We found no evidence that CR rates differed between different chemotherapy drug types, but amongst different cancer types small CR differences were evident, although none exceeded a mean CR rate of 11{\%}. This remarkable concordance of CR rates regardless of cancer or therapy type remains currently unexplained, and motivates further investigation.",
author = "Derek Abbott and Ashdown, {Martin L.} and Robinson, {Andrew P.} and Yatomi-Clarke, {Steven L.} and Ashdown, {M. Luisa} and Andrew Allison and Markovic, {Svetomir Nenad} and Coventry, {Brendon J.}",
year = "2015",
doi = "10.12688/f1000research.6760.1",
language = "English (US)",
volume = "4",
pages = "1",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Chemotherapy for Late-Stage Cancer Patients

T2 - Meta-Analysis of Complete Response Rates

AU - Abbott, Derek

AU - Ashdown, Martin L.

AU - Robinson, Andrew P.

AU - Yatomi-Clarke, Steven L.

AU - Ashdown, M. Luisa

AU - Allison, Andrew

AU - Markovic, Svetomir Nenad

AU - Coventry, Brendon J.

PY - 2015

Y1 - 2015

N2 - Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are generally low, with few exceptions, regardless of the solid cancer type or drug regimen. We investigated CR rates reported in the literature for clinical trials using chemotherapy alone, across a wide range of tumour types and chemotherapeutic regimens, to determine an overall CR rate for late-stage cancers. A total of 141 reports were located using the PubMed database. A meta-analysis was performed of reported CR from 68 chemotherapy trials (total 2732 patients) using standard agents across late-stage solid cancers-a binomial model with random effects was adopted. Mean CR rates were compared for different cancer types, and for chemotherapeutic agents with different mechanisms of action, using a logistic regression. Our results showed that the CR rates for chemotherapy treatment of late-stage cancer were generally low at 7.4%, regardless of the cancer type or drug regimen used. We found no evidence that CR rates differed between different chemotherapy drug types, but amongst different cancer types small CR differences were evident, although none exceeded a mean CR rate of 11%. This remarkable concordance of CR rates regardless of cancer or therapy type remains currently unexplained, and motivates further investigation.

AB - Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are generally low, with few exceptions, regardless of the solid cancer type or drug regimen. We investigated CR rates reported in the literature for clinical trials using chemotherapy alone, across a wide range of tumour types and chemotherapeutic regimens, to determine an overall CR rate for late-stage cancers. A total of 141 reports were located using the PubMed database. A meta-analysis was performed of reported CR from 68 chemotherapy trials (total 2732 patients) using standard agents across late-stage solid cancers-a binomial model with random effects was adopted. Mean CR rates were compared for different cancer types, and for chemotherapeutic agents with different mechanisms of action, using a logistic regression. Our results showed that the CR rates for chemotherapy treatment of late-stage cancer were generally low at 7.4%, regardless of the cancer type or drug regimen used. We found no evidence that CR rates differed between different chemotherapy drug types, but amongst different cancer types small CR differences were evident, although none exceeded a mean CR rate of 11%. This remarkable concordance of CR rates regardless of cancer or therapy type remains currently unexplained, and motivates further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84969677663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969677663&partnerID=8YFLogxK

U2 - 10.12688/f1000research.6760.1

DO - 10.12688/f1000research.6760.1

M3 - Article

VL - 4

SP - 1

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 232

ER -